ReferencesBhoola SM, Coleman RL, Herzog T, et al. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. Gynecol Oncol. 2004;95:564-569. du Bois A, Luck HJ, Pfisterer J, et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer—a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol. 2001;12:1115-1120. Ferrero J, Weber B, Lepille D, et al. Carboplatin (PA) and pegylated liposomal doxorubicin (CA; PACA regimen) in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): Survival results of a GINECO phase II trial. J Clin Oncol. 2004;22. Abstract 5022. GOG 184. A randomized phase III study of tumor volume directed pelvic plus or minus para-aortic irradiation followed by cisplatin and doxorubicin or cisplatin, doxorubicin and paclitaxel for advanced endometrial carcinoma. National Cancer Institute Web site. Available at: http://ctep.cancer.gov/resources/gcig/activetrials.html. Accessed June 3, 2005. GOG 146Q. A phase II evaluation of topotecan (NSC #609699) administered daily x 5 every 3 weeks vs. weekly topotecan in the treatment of recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal carcinoma. Columbia River Oncology Program (CROP) Clinical Research Studies Adult Open List (May 23, 2005). Available at: http://www.cropor.org/. Accessed June 3, 2005. Gordon AN, Fleagle J, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95:1-8. Ledermann JA. Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR 2.2). Proc Am Soc Clin Oncol. 2003;22:446. Abstract 1794. Levy T, Inbar M, Menczer J, et al. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol. 2004;95:686-690. Long HJ, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin (P) vs cisplatin plus topotecan (T) vs MVAC in stage IVB, recurrent or persistent carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Paper presented at: Society of Gynecologic Oncologists 35th Annual Meeting; February 6-11, 2004: San Diego, Calif. Mariani A, Webb MJ, Keeney GL, et al. Endometrial cancer: predictors of peritoneal failure. Gynecol Oncol. 2003;89:236-242. Mariani A, Webb MJ, Keeney GL, et al. Stage IIIC endometrioid corpus cancer includes distinct subgroups. Gynecol Oncol. 2002;87:112-117. McMeekin DS, Lashbrook D, Gold M, et al. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001;81:273-278. Monk BJ, Huang H, Wenzel L, et al. Quality of life outcomes from a phase III trial of cisplatin vs. cisplatin plus topotecan in stage IVB, recurrent of persistent carcinoma of the cervix: results of GOG protocol 179. Paper presented at: Society of Gynecologic Oncologists 35th Annual Meeting; February 6-11, 2004; San Diego, Calif. Morris RT, Alvarez RD, Malone J, et al. Phase II study of weekly topotecan in patients with relapsed platinum-sensitive ovarian or peritoneal cancer. J Clin Oncol. 2005;23. Abstract 5058. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40:55-65. Morrow CP, Curtin JP, eds. Gynecologic Cancer Surgery. New York, NY: Churchill-Livingstone Publishing Co; 1996. Mundt AJ, Murphy KT, Rotmensch J, et al. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys. 2001;50:1154-1160. Nelson G, Randall M, Sutton G, et al. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. Gynecol Oncol. 1999;75:211-214. Onda T, Yoshikawa H, Mizutani K, et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer. 1997;75:1836-1841. Pfisterer J, Plante M, Vergote, et al. Gemcitabine/ Randall ME, Brunetto G, Muss H, et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol. 2003;22:2. Abstract 3. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1999;17:2676-2680. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2177-2180. |